Peer-influenced content. Sources you trust. No registration required. This is HCN.
Conexiant
The FDA approved a supplemental NDA adding randomized withdrawal trial data to the lumateperone label, supporting its role in long-term maintenance and relapse prevention in adults with schizophrenia.
Psychiatry May 13th 2026
Parkinson’s News Today
Switching Parkinson’s patients to Crexont added more than three hours of daily symptom control in interim Phase 4 data. Here’s how to read an open-label, sponsor-run signal.
Neurology April 30th 2026
Annals of Internal Medicine
The OSPREY trial puts proximal hypoglossal nerve stimulation on the map for moderate-to-severe OSA, with strong short-term numbers and the limitations a small unblinded RCT carries.
Medical Professionals Reference (MPR)
Sdamlo’s FDA approval offers a new oral solution option for delivering amlodipine, addressing administration challenges in patients who cannot tolerate tablets.
Cardiology April 24th 2026
Healthline
“There is enormous exuberance about starting GLP-1 drugs, but not nearly enough attention to what happens when people stop.” – Senior study author Ziyad Al-Aly, MD; Washington University School of Medicine
Cardiology March 27th 2026
Health
The best exercise is one you can do and enjoy doing consistently. Many people give up on exercising because it feels too hard, too boring, or inconvenient.
Cardiovascular Nursing January 29th 2026
DIET & NUTRITION 
PATIENT EDUCATION 
OBESITY/WEIGHT MANAGEMENT 
EXERCISE/TRAINING 
LEGAL MATTERS 
GUIDELINES/RECOMMENDATIONS